ClinicalTrials.gg
CompletedNCT00163046Updated Feb 2, 2021

A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

A Phase 3 interventional study of Gabapentin and Placebo in Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.

Enrollment
8th of 14
256 · median 283
Started
2005
with 2 others
Phase 3
9 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
9 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 8th largest by enrollment, is one of 3 that started in 2005, is one of 9 in phase 3, and was the 1st registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders as a file.
02

Study summary

The purpose of this study is to to assess the effect of gabapentin compared to placebo on sleep, using polysomnography along with subjective sleep assessments, in subjects with transient insomnia induced by a sleep phase advance.

03

Conditions studied

  • Transient Insomnia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older with occasional sleeplessness in the month prior to screening

Exclusion criteria

Exclusion Criteria:

  • Current treatment for, or recent history (within 2 years) of, a sleeping disorder including excessive snoring, obstructive sleep apnea or a chronic painful condition that interferes with the subject's sleep
  • Currently taking or expected to take any of the following during trial: amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates, propoxyphene, barbiturates, and phencyclidine during their participation in the trial
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Gabapentin

    Drug: Gabapentin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days

  • DrugPlacebo

    Matched placebo 30 minutes prior to bedtime for 28 days

06

What researchers measure

Primary outcomes

  1. Polysomnographic (PSG) measurement of Wake after Persistent Sleep Onset (WAPSO)

    Time frame: Day 1

Secondary outcomes

  1. PSG WAPSO

    Time frame: Day 28

  2. PSG Latency to Persistent Sleep (LPS)

    Time frame: Days 1 and 28

  3. PSG Sleep Onset Latency (SOL)

    Time frame: Days 1 and 28

  4. PSG Number of Awakenings (NAW)

    Time frame: Days 1 and 28

  5. PSG Wake after Sleep Onset (WASO)

    Time frame: Days 1 and 28

  6. PSG Total Wake Time (TWT) plus Stage 1 Sleep

    Time frame: Days 1 and 28

  7. PSG Wake Time During Sleep (WTDS)

    Time frame: Days 1 and 28

  8. PSG Total Sleep Time (TST)

    Time frame: Days 1 and 28

  9. PSG Sleep Efficiency (SE)

    Time frame: Days 1 and 28

  10. PSG Percent of Stages 1, 2, 3, 4 and REM sleep

    Time frame: Days 1 and 28

  11. PSG Percent Slow Wave Sleep (SWS, Stages 3&4 combined)

    Time frame: Days 1 and 28

  12. Subjective SL

    Time frame: Days 1 and 28

  13. Subjective NA

    Time frame: Days 1 and 28

  14. Subjective WASO

    Time frame: Days 1 and 28

  15. Subjective TST

    Time frame: Days 1 and 28

  16. Subjective ASR

    Time frame: Days 1 and 28

  17. Subjective ASQ

    Time frame: Days 1 and 28

  18. Karolinska Sleep Diary (KSD)-Sleep Quality Index

    Time frame: Days 1 and 28

  19. KSD individual scores

    Time frame: Days 1 and 28

  20. Vital signs

    Time frame: Days 1 and 28

  21. Adverse events

    Time frame: Through Day 32

07

Study locations

3 sites
  • Pfizer Investigational Site
    Glendale, California 91206, United States
  • Pfizer Investigational Site
    San Diego, California 92123, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66212, United States
08

References and documents

Publications

  • Furey SA, Hull SG, Leibowitz MT, Jayawardena S, Roth T. A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014 Oct 15;10(10):1101-9. doi: 10.5664/jcsm.4110. PubMed 25317091 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 13, 2005
Start
Oct 2005
CompletionActual
Apr 2006
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00163046
Responsible party
Sponsor
First posted
Sep 13, 2005
Start date
Oct 2005
Completion
Apr 2006
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion